Femasys, Inc. (FEMY)
NASDAQ:FEMY
Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$0.31 - $1.22
Previous CloseN/A
Volume25.00K
Average Volume (3M)560.35K
Market Cap
$22.05M
Enterprise Value$6.41M
Total Cash (Recent Filing)$9.27M
Total Debt (Recent Filing)$4.70M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding60,390,686
10 Day Avg. Volume395,300
30 Day Avg. Volume560,348
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.94
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue2.80
Enterprise Value/Gross Profit4.51
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$2.25Price Target Upside208.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$4.61M
Bulls Say, Bears Say
Bulls Say
Niche Product FocusFemasys’ concentrated portfolio in women’s reproductive diagnostics—FemVue and related consumables—targets a structurally resilient fertility and women's health market. Specialized devices and consumable sales create recurring revenue and clinical stickiness, supporting steady adoption and durable demand over months.
Improved Balance Sheet LeverageMaterial reduction in leverage in 2025 lowers short-term solvency risk and gives management more flexibility to allocate capital to commercialization and operations. Improved debt-to-equity meaningfully reduces default probability and supports funding optionality during multi-quarter scale-up efforts.
Strengthened Operational LeadershipHiring an experienced med‑tech operations executive enhances capacity to scale manufacturing, tighten supply chains and execute global commercialization. Durable improvements in operations and quality control can lower unit costs and support sustainable margin improvement as sales scale.
Bears Say
Heavy Cash BurnPersistently large negative operating and free cash flow in 2025 indicates structural cash consumption that likely requires repeated external financing. Ongoing cash burn constrains the company's ability to self-fund commercialization, increases dilution risk, and limits durable investment in growth initiatives.
Persistent Losses & Weak MarginsModest revenue growth off a small base alongside collapsing gross profit and negative net margins point to structural margin pressure from pricing, cost mix, or one-time effects. Sustained negative profitability undermines the path to self-sustaining cash generation and long-term operating leverage.
Significant Dilution & Listing RiskAuthorization for a reverse split and the potential issuance of large equity on conversion/warrant exercise creates durable dilution risk and highlights Nasdaq compliance pressure. Continued lender influence and financing-driven governance actions can impair shareholder value and strategic flexibility over many quarters.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $0.31 and its highest was $1.22 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $22.05M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is May 07, 2026 which is in 4 days.
How were Femasys, Inc.’s earnings last quarter?
Femasys, Inc. released its earnings results on Mar 31, 2026. The company reported -$0.063 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.004.
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 60,390,686 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Femasys, Inc. reported an EPS of -$0.063 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.714%.
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
FEMY Stock 12 Month Forecast
Average Price Target
$2.25
▲(208.22% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
3.01% Insiders
2.50% Mutual Funds
0.69% Other Institutional Investors
91.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---